{"schema_version":"secwatch.filing_event.v1","accession":"0001554859-24-000013","form_type":"8-K","ticker":null,"cik":"0001554859","company_name":"Semler Scientific, Inc.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.937550+00:00","generated_at":"2026-06-02T18:09:58.255275+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Semler Scientific Q1 revenue down 13% to $15.9M; net income up 22% to $6.1M","bullets":["Revenue of $15.9M, down 13% YoY; fixed-fee software license revenue fell 24% to $7.1M.","Net income of $6.1M ($0.78 diluted EPS) vs. $5.0M ($0.63) a year ago; operating expenses dropped 25%.","Cash and equivalents grew to $62.9M from $57.2M at year-end 2023, driven by strong cash generation.","CEO cites regulatory-driven revenue decline from PAD product; expects re-acceleration if new FDA 510(k) is obtained.","Three largest customers comprised 45%, 25%, and 11% of Q1 2024 revenue."],"urls":{"canonical":"https://secwatch.observer/filing/0001554859-24-000013","json":"https://secwatch.observer/filing/0001554859-24-000013.json","markdown":"https://secwatch.observer/filing/0001554859-24-000013.md","text":"https://secwatch.observer/filing/0001554859-24-000013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1554859/000155485924000013/0001554859-24-000013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1554859/000155485924000013/smlr-20240507x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T18:09:58.255275+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a4c356f9c9481072fba830239c3eb78b3d20b1cf","claim":"Semler Scientific, Inc. reported first quarter ended March 31, 2024 results: revenue $15.9 million, net income $6.1 million, EPS $0.88 per basic share and $0.78 per diluted share.","evidence_excerpt":"(EX-99.1) --- Semler Scientific® Reports First Quarter 2024 Financial Results 2024 Q1 highlights compared to the corresponding period of 2023: ​ ● First quarter revenues were $15.9 million, a decrease of 13% ● First quarter net income was $6.1 million, an increase of 22% ● Cash, cash equivalents and restricted cash balance increased to $62.9 million ​ S anta Clara,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1554859/000155485924000013/0001554859-24-000013-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$15.9 million"},{"label":"Net income","value":"$6.1 million"},{"label":"EPS","value":"$0.88 per basic share and $0.78 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}